EYPT · EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals reported first quarter 2026 financial results that reflect the company's heavy investment in its lead pipeline candidate DURAVYU. Total net revenue plummeted to $0.7 million from $24.5 million in the prior year period, primarily due to the recognition of remaining deferred revenue from the 2023 YUTIQ license agreement in the prior year. Operating expenses rose to $87.9 million from $73.3 million, driven by ongoing Phase 3 clinical trials for DURAVYU in wet AMD and DME, as well as scale-up of the commercial manufacturing facility. Net loss widened to $84.8 million ($0.99 per share) from $45.2 million ($0.65 per share) in Q1 2025. The company ended the quarter with $223 million in cash and investments, down from $306 million at year-end 2025, but sufficient to fund operations into the fourth quarter of 2027. Management highlighted that Phase 3 wet AMD trials (LUGANO and LUCIA) remain on track for topline data beginning mid-2026, and the Phase 3 DME program (COMO and CAPRI) has enrolled over one-third of patients with full enrollment expected in Q3 2026. Interim masked safety data for DURAVYU remain consistent with prior trials, with no safety signals. The company also presented new preclinical data at ARVO 2026 demonstrating vorolanib's inhibition of IL-6 signaling via JAK1, supporting DURAVYU's multi-mechanism of action. The financial results underscore the pre-revenue, clinical-stage nature of EyePoint, with investor focus squarely on upcoming Phase 3 data readouts that could determine DURAVYU's commercial potential in the large wet AMD and DME markets.